

# Uganda

Population 2015

39 million

| Estimates of TB burden*, 2015 | Number (thousands) | Rate (per 100 000 population) |
|-------------------------------|--------------------|-------------------------------|
| Mortality (excludes HIV+TB)   | 5.5 (3.3–8.3)      | 14 (8.5–21)                   |
| Mortality (HIV+TB only)       | 6.4 (1.7–14)       | 16 (4.3–36)                   |
| Incidence (includes HIV+TB)   | 79 (47–119)        | 202 (120–304)                 |
| Incidence (HIV+TB only)       | 26 (16–37)         | 66 (42–94)                    |
| Incidence (MDR/RR-TB)**       | 1.9 (1–2.8)        | 4.9 (2.6–7.2)                 |

| Estimated TB incidence by age and sex (thousands)*, 2015 |               |             |             |
|--|---------------|-------------|-------------|
|  | 0-14 years    | > 14 years  | Total       |
| Females  | 3.2 (1.2–5.3) | 23 (5.8–41) | 27 (7–46)   |
| Males  | 3.8 (2.2–5.3) | 48 (32–64)  | 52 (34–70)  |
| Total  | 7 (4.5–9.5)   | 72 (52–91)  | 79 (47–119) |

| TB case notifications, 2015                            |        |
|--|--------|
| Total cases notified                                   | 43 736 |
| Total new and relapse                                  | 41 912 |
| - % tested with rapid diagnostics at time of diagnosis |        |
| - % with known HIV status                              | 100%   |
| - % pulmonary  | 91%    |
| - % bacteriologically confirmed among pulmonary        | 71%    |

| Universal health coverage and social protection                        |                  |
|--|------------------|
| TB treatment coverage (notified/estimated incidence), 2015             | 53% (35–89)      |
| TB patients facing catastrophic total costs                            |                  |
| TB case fatality ratio (estimated mortality/estimated incidence), 2015 | 0.16 (0.07–0.31) |

| TB/HIV care in new and relapse TB patients, 2015    |        |     |  |
|---|--------|-----|--|
|   | Number | %   |  |
| Patients with known HIV-status who are HIV-positive | 17 642 | 42% |  |
| - on antiretroviral therapy                         | 15 448 | 88% |  |

| Drug-resistant TB care, 2015                                |                 |                           |                   |
|---|-----------------|---------------------------|-------------------|
|   | New cases       | Previously treated cases  | Total number***   |
| Estimated MDR/RR-TB cases among notified pulmonary TB cases |                 |                           | 1 000 (660–1 400) |
| Estimated % of TB cases with MDR/RR-TB                      | 1.6% (0.78–2.4) | 12% (5.9–18)              |                   |
| % notified tested for rifampicin resistance                 | 8%              | 37%                       | 6 827             |
| MDR/RR-TB cases tested for resistance to second-line drugs  |                 |                           | 252               |
| Laboratory-confirmed cases                                  |                 | MDR/RR-TB: 252, XDR-TB: 0 |                   |
| Patients started on treatment ****                          |                 | MDR/RR-TB: 253, XDR-TB: 0 |                   |

| Treatment success rate and cohort size                          |         |        |
|---|---------|--------|
|   | Success | Cohort |
| New and relapse cases registered in 2014                        | 75%     | 43 628 |
| Previously treated cases, excluding relapse, registered in 2014 | 67%     | 2 438  |
| HIV-positive TB cases, all types, registered in 2014            | 73%     | 16 670 |
| MDR/RR-TB cases started on second-line treatment in 2013        | 73%     | 214    |
| XDR-TB cases started on second-line treatment in 2013           |         | 0      |

| TB preventive treatment, 2015   |  |
|---|--|
| % of HIV-positive people (newly enrolled in care) on preventive treatment                                   |  |
| % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment |  |

| TB financing, 2016   |    |
|--|----|
| National TB budget (US\$ millions)                           | 38 |
| Funding source: 4% domestic, 78% international, 19% unfunded |    |

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


## Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015




Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



— Unfunded  
— Funded internationally  
— Funded domestically